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Background: Despite the availability of several antihypertensive medications, the morbidity and mortality caused
by hypertension is on the rise, suggesting the need for investigation of novel signaling pathways involved in its
pathogenesis. Recent evidence suggests the role of toll-like receptor (TLR) 4 in various inflammatory diseases,
including hypertension. The role of the brain in the initiation and progression of all forms of hypertension is well
established, but the role of brain TLR4 in progression of hypertension has never been explored. Therefore, we
investigated the role of TLR4 within the paraventricular nucleus (PVN; an important cardioregulatory center in the
brain) in an animal model of human essential hypertension. We hypothesized that a TLR4 blockade within the PVN
causes a reduction in mean arterial blood pressure (MAP), inflammatory cytokines and sympathetic drive in
hypertensive animals.
Methods: Spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto (WKY) rats were administered
either a specific TLR4 blocker, viral inhibitory peptide (VIPER), or control peptide in their PVN for 14 days. MAP was
recorded continuously by radiotelemetry. PVN and blood were collected for the measurement of pro-inflammatory
cytokines (Tumor Necrosis Factor (TNF)-α, interleukin (IL)-1β), anti-inflammatory cytokine IL-10, inducible nitric oxide
synthase (iNOS), TLR4, nuclear factor (NF) κB activity and plasma norepinephrine (NE) and high mobility group box
(HMGB)1 expression, respectively.
Results: Hypertensive rats exhibited significantly higher levels of TLR4 in the PVN. TLR4 inhibition within the PVN
attenuated MAP, improved cardiac hypertrophy, reduced TNF-α, IL-1β, iNOS levels, and NFκB activity in SHR but not
in WKY rats. These results were associated with a reduction in plasma NE and HMGB1 levels and an increase in IL-10
levels in SHR.
Conclusions: This study demonstrates that TLR4 upregulation in PVN plays an important role in hypertensive
response. Our results provide mechanistic evidence that hypertensive response in SHR are mediated, at least in part,
by TLR4 in the PVN and that inhibition of TLR4 within the PVN attenuates blood pressure and improves
inflammation, possibly via reduction in sympathetic activity.
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According to current statistics, hypertension affects
more than 33% of US adults [1] and it has emerged as
one of the most common chronic disease in the United
States. Hypertension is characterized by elevated blood
pressure, cardiac hypertrophy and chronic low-grade in-
flammation. Several mechanisms that have been shown
to exist in hypertension include excessive vasoconstric-
tion, commonly involving the endogenous peptides,
angiotensin II and endothelin, or deficient vasodilatation,
often involving nitric oxide (NO), dysregulation of ad-
renergic mechanisms [2], increase in the total peripheral
resistance either due to increase in the contractile re-
sponses or a decrease in relaxant responses in resistance
arteries [3]. Nevertheless, uncontrolled hypertension
may lead to various end organ injuries including, but
not limited to, cardiac remodeling [4-6], renal dysfunc-
tion [5,6] , retinopathy [7] coronary heart disease, heart
failure and stroke. A critical player leading all these
events is the immune system, which does so by partici-
pating in an inflammatory cascade in the cardiovascular,
renal and central nervous system (CNS) [8-10]. In the
CNS, the brain is the central organ playing an important
in fluid homeostasis and sympathetic regulation of blood
pressure (BP). Unlike previous studies indicating the role
played by the brain in late stage hypertensive disease, a
growing body of evidence suggests the role of the brain
in the initiation and progression of all forms of hyper-
tension including essential hypertension [11].
Innate immunity is the first line of defense against
pathogens, which is initiated by infection or tissue
insult. This critical response is initiated by identifica-
tion of pathogen-associated molecular patterns by
pathogen-recognition receptors present on cell mem-
brane [12]. One such pathogen-recognition receptor
includes toll-like receptors (TLRs), which are major
components of the innate immune system. TLR is an
evolutionarily conserved receptor family that was ini-
tially discovered to be responsible for determining the
dorsal-ventral axis in Drosophila. Later, TLRs were
found controlling host defense against microbes in
plants, vertebrates, and mammals. A total of 13 iso-
forms of TLRs (TLR1, 2, 3, etcetera) have been identi-
fied in mammalian cells, including leukocytes,
cardiomyocytes and endothelial cells [13,14], each
of which recognizes specific pathogen-associated
molecular patterns (PAMPs) or damage-associated
molecular patterns (DAMPs). Of several DAMPs, high
mobility group box-1 (HMGB1) is the most important
DAMP that has been implicated in various inflamma-
tory conditions. In response to injury or infection,
HMGB1 is released actively by immune cells and pas-
sively by insulted cells into the extracellular space and
initiates an inflammatory response [15-17].Hypothalamic paraventricular nucleus (PVN) is the
most important cardiovascular regulatory center within
the brain, playing a major role in sympathetic control of
BP. The PVN regulates sympathetic output, baroreflex
function and salt appetite [4,18], thus acting as an im-
portant endocrine-autonomic control area in the brain.
Evidence suggests that the increased pro-inflammatory
cytokines(PICs) within the PVN of the brain play an im-
portant role in the development of hypertension [19,20].
It has been observed that, administration of PICs into
the PVN causes increased renal sympathetic output and
mean arterial pressure [21]. A cytokine-induced increase
in inducible nitric oxide synthase (iNOS) has also been
found to assist in the development of hypertension
[22,23]. It is now well established that an increase in
PICs causes increased production of reactive oxygen
species (ROS), leading to increased activity of down-
stream transcription factor, nuclear factor-kappa B
(NFκB), which in turn further upregulates PICs. This vi-
cious cycle ultimately contributes to an altered patho-
physiologic phenotype and high blood pressure.
A growing body of evidence suggests the innate im-
mune system plays a role in several inflammatory pro-
cesses affecting the cardiovascular system, including
hypertension. Although TLR is a critical component of
the innate immune system, the role of TLR in the eti-
ology of hypertension is not well understood. Based on
previous reports from our laboratory and others, out of
13 TLRs, TLR4 can be implicated in the pathogenesis of
hypertension. Given the role of PVN in initiation of high
blood pressure, it is imperative to investigate the role of
TLR4 within the PVN in modulating inflammatory re-
sponse in hypertension. In addition, the underlying mo-
lecular mechanisms in TLR4 mediated inflammatory
response in hypertension have never been studied.
Therefore, we hypothesize that TLR4 signaling in the
PVN of the brain might be one of the main factors for
the establishment of hypertension and cardiac remodel-
ing observed in the SHR rats. In this study, we aim to in-
vestigate the role of TLR4 in the PVN of SHR rats, a
model of human essential hypertension, and evaluate if
the TLR4 blockade within the PVN has any protective
role in hypertension, cardiac function, inflammatory cy-
tokines in the brain and plasma, and sympathetic activ-
ity. The outcomes of this study will help us to
understand pathogenesis of hypertension and develop
newer therapeutics for its effective control.Methods
Ethics statement
All of the animal procedures in this study were reviewed
and approved by the Louisiana State University Institutional
Animal Care and Use Committee (IACUC) in accordance
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Experimental design
Male spontaneously hypertensive (SHR) rats and their
normotensive control Wistar Kyoto (WKY) rats (10 to
12 weeks old, 230 to 340 g) were used in this study.
They were housed in temperature-controlled (23 ± 2°C)
and light-controlled (lights on between 7 AM and 7 PM)
animal quarters and were provided with chow ad libi-
tum. The rats were surgically implanted with radiotelem-
etry transmitters for continuous monitoring of mean
arterial pressure (MAP). Bilateral canulae were im-
planted into the PVN of these animals for infusion of
viral inhibitory peptide of TLR4 (VIPER, a specific TLR4
receptor blocker; Imagenex Corp, San Diego, CA, USA)
or control peptide (CP) (40 μg/kg/day; Imagenex Corp,
San Diego, CA, USA) dissolved in aCSF (artificial CSF)
through osmotic minipump (14 days, infusion rate
0.11 μl/h; Alzet, model 1004) for two weeks. VIPER spe-
cifically inhibit TLR4 signaling by binding its adaptor
proteins Mal/TIRAP and TRAM [24,25].The dose of the
VIPER used was assessed from a pilot study in rats
where three different doses of 10, 40 and 160 μg/kg/day
were used. The 40 μg/kg/day was found to be optimal,
whereas the highest dose caused mortality and lowest
dose did not produce complete inhibition of TLR4 re-
ceptors as measured by immunofluorescence staining
and western blot results (data not shown). The rats were
divided into four groups (n =20/group): (1) WKY + CP;
(2) WKY + VIPER; (3) SHR + CP; (4) SHR + VIPER. At
the end of the study, rats were euthanized using CO2 in-
halation; the brains and heart tissues (left ventricle) were
collected, and immediately frozen on dry ice until fur-
ther analysis.
Blood pressure measurements
MAP was recorded continuously in conscious rats
(n = 14/group) using surgically implanted radio-telemetry
transmitters (Model TA11PA-C40, Data Sciences
International, St. Paul, MN, USA), as described previously
[26,27]. The rats were anesthetized with a ketamine
(90 mg/kg) and xylazine (10 mg/kg) mixture (i.p.) and
placed dorsally on a heated surgical table. Limb with-
drawal response to toe pinching was used to ascertain the
adequacy of anesthesia. Through a small incision on the
ventral surface of left leg, femoral artery and vein were ex-
posed and dissected apart. The femoral artery was ligated
distally, and a small clamp was applied to temporarily stop
the blood flow. The catheter tip was introduced through a
small incision in the femoral artery, advanced into the ab-
dominal aorta such that the catheter tip was distal to the
renal arteries, and secured in place. The transmitter body
was placed in to the abdominal cavity and secured to theabdominal wall. Following implantation, abdominal mus-
culature and skin layers were sutured and closed. After
surgery, all rats received benzathine penicillin (30,000 U, i.
m.) and buprenorphine (0.1 mg/kg, s.c.), which was
repeated 12 h postoperatively. The rats were allowed to
recover for 7 days from surgical trauma.Intra-paraventricular nucleus cannula implantation
The rats were implanted with intra-PVN cannula for in-
fusion of VIPER or CP, as described previously [19].
Briefly, the rats were anesthetized with a ketamine
(90 mg/kg) and xylazine (10 mg/kg) mixture (i.p.),
and then placed in a stereotaxic instrument (Kopf
instruments; Tujunga, CA). The adequacy of anesthesia
was monitored by limb withdrawal response to toe
pinching. Bregma was identified and according to
Paxinos and Watson [28] rat atlas, coordinates for the
PVN were obtained at 1.8 mm posterior and 7.9 mm
ventral to the zero level. A custom-made bilateral can-
nulae (Plastic One; Roanoke, VA, USA) was implanted
in to the PVN of animals, and fixed to the cranium using
small screws and dental cement. A 14-day miniosmotic
pump was implanted subcutaneously and connected to
the infusion cannula through a sterile vinyl tubing to de-
liver VIPER or CP in the PVN of the brain. Cannula
placement within the PVN was examined during cryo-
stat slicing with crystal violet staining prior to PVN
punching and immunofluorescence sectioning. Rats that
had malfunctioning pumps (such as tube detachment
from pump or cannula, based on postmortem analysis)
or received unilateral treatment into the PVN were
removed from the final analysis (success rate: bilateral
cannulation, 80%; n = 25).Paraventricular nucleus collection, RNA isolation, and
real-time RT-PCR
Freshly frozen brains were cut on a cryostat to get cor-
onal brain sections, which were mounted on slides for
punch microdissection. The PVN punches were made
from the frozen brain sections using Stoelting brain
punch (Stoelting, IL, USA) as described earlier [29,30].
Semi-quantitative real-time RT-PCR was used to deter-
mine the mRNA levels of TNF-α, IL-1β, IL-10, iNOS,
and TLR4 in the PVN tissues (n = 8/group) and ANP
(Atrial Natriuretic Peptide- a marker of cardiac hyper-
trophy) in left ventricular tissues by using specific
primers (Table 1). Total RNA isolation, cDNA synthesis
and RT-PCR were performed as previously described
[31]. DNAase- treatment was performed to prevent
cDNA contamination from genomic DNA. Semi-log
amplification curves were evaluated by the comparative
quantification method (2-ΔΔCT), and GAPDH was used
for normalization of all reported gene expression levels.








IL, Interleukin; TNF-α, Tumor necrosis factor-alpha; iNOS, Inducible nitric oxide
synthase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; TLR4, Toll-like
receptor 4.
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interest relative to that of the control group.Western blot analysis
The tissue homogenate from the PVN was subjected to
western blot analysis (n = 6/group) for determination of
protein levels of PICs (TNF-α, IL-1β), IL-10, iNOS,
TLR4 and GAPDH. The western blot was performed by
standard protocol, as described previously [32]. Briefly,
the heart tissues were homogenized in 500 ul (100 μl for
PVN tissue) of RIPA (Radioimmunoprecipitation Assay
Buffer) lysis buffer (Cell Signaling Technology, Inc., MA,
USA) containing protease inhibitor cocktail. The protein
was extracted from the homogenates, and the protein
concentration in the lysate was measured using a Brad-
ford assay using BSA standards. Protein extracts (40 μg)
were combined with an equal volume of 2X Laemmli
loading buffer, boiled for 5 minutes and electrophoresed
on 10 to 15% SDS-polyacrylamide gels. The proteins
were then electroblotted onto polyvinylidene fluoride
membranes (Immobilon-P, Millipore, MA, USA). Non-
specific binding was blocked by incubating the mem-
branes in 1% casein in phosphate-buffered saline-Tween
for 1 h at room temperature (RT). Blots were then incu-
bated overnight at 4°C with the primary antibodies.
Specific antibodies used included TNF-α, IL-1β, iNOS,
GAPDH, and TLR4, at 1:1,000 dilution; IL-10, at 1:500
dilution. The following antibodies were commercially
obtained: TNF-α, and TLR4 (mouse monoclonal; Abcam
Inc, MA; ab22048); IL-1β, iNOS, and GAPDH (Santa
Cruz Biotechnology, Santa Cruz, CA, USA); and IL-10
(Abbiotec, LLC, San Diego, CA, USA). After washing
with wash buffer (1X TBS, 0.1% Tween-20) four times
for 10 min each time at RT, blots were then incubated
for 1 h with secondary antibody (1:10,000 dilution, Santa
Cruz Biotechnology, CA, USA) labeled with horseradish
peroxidase. Immunoreactive bands were visualized using
enhanced chemiluminescence (ECL Plus, Amersham,
GE Healthcare Bio-Sciences, PA, USA), band intensities
were quantified using a VersaDoc MP 5000 imagingsystem (Bio-Rad, CA, USA), and bands were normalized
with GAPDH.Immunofluorescence double labeling
Immunofluorescence procedures were carried out as
previously described [33]. Coronal brain sections were
cut with a freezing microtome (Leica, NJ, USA) at
25 μm at the mid-rostrocaudal levels of the PVN as de-
scribed earlier [34]. Briefly, sections were preincubated
with 1% H2O2 in 0.1 M PBS (30 min), blocked with 2%
normal goat serum (KPL, CA, USA) (1 hr at room
temperature), and then incubated (overnight at 4°C)
with the primary antibodies in primary antibody
diluents (containing, normal goat serum 10% Triton X,
in 0.1 M PBS). Specific primary antibodies used
included mouse anti-TLR4 (1:500) (Abcam, USA;
mouse monoclonal, ab22048), rabbit anti-TLR4
(1:1000; ab13556), rabbit anti-Neuronal Nuclei (NeuN)
(1:500) (Abcam, MA,USA), rabbit anti-glial fibrillary
acid protein (GFAP) (1:100) (Abcam, MA, USA), or
mouse anticluster of differentiation 11b (CD11b)
(1:500) (Abcam, MA, USA). Conjugated secondary
antibodies were used to detect the primary antibody,
which included Alexa Fluor 594 goat anti-mouse IgG
(H + L) (1:1000), Alexa Fluor 488 goat anti-rabbit IgG
(H + L) (1:1000) (Cell Signaling Technology, MA,
USA), or fluorescein isothiocyanate-goat anti-mouse
IgG antibodies (1:200) (Zymed, CA, USA) in 0.1 M
PBS (1 hr at RT), and then sections were mounted in
ProLong Gold antifade reagent (P36930, Invitrogen,
NY,USA). Immunoreactivity was visualized using the
BX53 microscope (Olympus America Inc, PA, USA)
and digitized at 20x and 40x using DP2-
BSWVer2.2software (https://support.olympus.co.jp/cf_
secure/en/lisg/bio/download/ga/dp2bsw0202/). Nega-
tive control sections were incubated with only PBS and
no positive staining was observed. As an additional
control, only the secondary antibody (in absence of the
primary) was used for TLR4, which prevented TLR4
staining (data not shown).Determination of NFκB activity in the paraventricular
nucleus
The binding activity of free NFκB/p65 in nuclear ex-
tracts of PVN tissue (n = 6/group) was assessed using an
ELISA kit (Active Motif, CA, USA). The method of ex-
traction and data analysis was as per the manufacturer’s
guidelines and as described previously [19]. This proced-
ure yields 0.15 to 0.25 mg of PVN tissue nuclear extract
at 3 to 5 mg/ml. Active ELISA detection levels for
NFκB/p65 from nuclear extracts were 0.5 to 1 μg per
well at 450 nm.
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Norepinephrine (NE) and HMGB1 were measured in
plasma samples (n =8/group) using a norepinephrine
ELISA kit (Abnova, Taiwan) and a HMGB1 ELISA kit
(MyBioSource, CA, USA), respectively as per the manu-
facturer’s guidelines.
Statistical analysis
All results are expressed as mean ± SEM. Statistical analysis
was done by either a two-way ANOVA or a one-way
ANOVA with a Bonferroni post hoc test using Graph Pad
Prism software (version 5.0; GraphPad Software, San Diego
California, USA). MAP data were analyzed by repeated-
measures ANOVA to examine with-in group changes over
time. A value of P <0.05 was considered statistically
significant.
Results
Toll-like receptor 4 is highly expressed in the neurons
and microglia of paraventricular nucleus in hypertensive
rats
Immunofluorescence staining of the PVN sections showed
that TLR4 is highly expressed in SHR+CP groups when
compared to WKY+CP (Figures 1, 2 and 3). Cell-type dis-
tribution of TLR4 was further investigated in the
PVN of all four groups using a double-labelingFigure 1 An immunofluorescence double labeling image (x 20) showing
TLR4 and NeuN in the PVN of WKY and SHR rats. n = 5/group. SHR + CP
neurons of PVN, whereas, VIPER infusion in these rats caused significant red
infusion in saline-infused rats did not have any effects. Scale bar 20 μm: CP, co
spontaneously hypertensive rat; TLR4, Toll-like receptor 4; VIPER, viral inhibitoryimmunofluorescence technique. The frozen floating sec-
tions were labeled with TLR4 antibody and one of the fol-
lowing: neuronal nuclei (NeuN), glial fibrillary acidic
protein (GFAP) or anti-CD11b antibodies. NeuN, GFAP
and anti-CD11b were used to identify neurons, astrocytes
and microglia, respectively. An overwhelming majority of
TLR4 (red) was co-localized with NeuN-positive neurons
(green) (Figure 1) in SHR + CP rats. Some of the TLR4-
positive cells (green) were also labeled with CD11b-
positive microglia/macrophage cells (red) (Figure 2);
whereas, almost none of the TLR4-positive cells (red) were
co-localized with GFAP-positive astrocytes (green) in the
PVN of SHR +CP rats (Figure 3). These results indicated
that TLR4 is mainly expressed in the neurons and micro-
glia of the PVN. Furthermore, chronic intra-PVN infusion
of VIPER in SHR caused an apparent reduction in TLR4
fluorescent staining in the PVN. These results corrobo-
rated with RT-PCR and western blot analysis confirming
the efficacy of VIPER in inhibiting TLR4 expression within
the PVN (Figure 4A-C).
Toll-like receptor 4 blockade reduced HMGB1 levels in
circulation and in the paraventricular nucleus of
hypertensive rats
SHR + CP group had increased gene and protein expres-
sion of HMGB1 when compared to WKY + CP ratsthe effects of intra-PVN infusion of VIPER on protein expression of
rats showed higher levels of immunofluorescence for TLR4 within the
uction in TLR4 expression. Arrow indicates double- labeled cells.VIPER
ntrol peptide; NeuN, neuronal nuclei; PVN, paraventricular nucleus; SHR,
peptide of TLR4; WKY, wistar-Kyoto.
Figure 2 An immunofluorescence double labeling image (x 40) showing the effects of intra-PVN infusion of VIPER on protein
expression of TLR4 and CD11B in the PVN of WKY and SHR rats. SHR + CP rats showed modest expression of TLR4 within the microglia
of PVN, whereas, VIPER infusion in these rats caused significant reduction in TLR4 expression. Arrow indicates double-labeled cells.VIPER
infusion in saline-infused rats did not have any effects. n = 5/group. Scale bar 20 μm : CD11B, cluster of differentiation molecule 11B; CP, control
peptide; PVN, paraventricular nucleus; SHR, spontaneously hypertensive rat; TLR4, Toll-like receptor 4; VIPER, viral inhibitory peptide of TLR4;
WKY, wistar-Kyoto.
Figure 3 An immunofluorescence double labeling image (x 20) showing the effects of intra-PVN infusion of VIPER on protein expression of
TLR4 and GFAP in the PVN of WKY and SHR rats. n = 5/group. Scale bar 20 μm : GFAP, glial fibrillary acidic protein; PVN, paraventricular
nucleus; SHR, spontaneously hypertensive rat; TLR4, Toll-like receptor 4; VIPER, viral inhibitory peptide of TLR4; WKY, wistar-Kyoto.
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Figure 4 Effects of PVN infusion of VIPER on gene and protein expression of TLR4 and HMGB1 in WKY and SHR rats. (A) mRNA
expression of TLR4; (B) protein expression of TLR4; (C) A representative immunoblot; (D) mRNA expression of HMGB1; (E) protein expression of
HMGB1; and (F) plasma levels of HMGB1. Values are means ± SE. n = 8 in each group for mRNA analysis, n = 5 in each group for western blot, and
n = 8 for plasma HMGB1. ***P <0.001 : HMGB1, high mobility group box 1; PVN, paraventricular nucleus; SHR, spontaneously hypertensive rat;
TLR4, Toll-like receptor 4; VIPER, viral inhibitory peptide of TLR4; WKY, wistar-Kyoto.
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HMGB1 was significantly higher in SHR + CP in com-
parison with WKY + CP rats (Figure 4F). Interestingly,
inhibition of TLR4 using VIPER in the PVN caused sig-
nificant reduction in plasma and PVN levels of HMGB1
in hypertensive rats when compared to WKY + CP
group. VIPER infusion did not affect HMGB1 in WKY
rats.
Toll-like receptor 4 blockade in the paraventricular
nucleus attenuated mean arterial pressure in
hypertensive rats
To assess the effect of inhibition of TLR4 in the PVN on
hypertensive response in animal model of essential
hypertension, MAP was continuously monitored usingimplanted radio-telemetry devise. As seen in Figure 5 A,
SHR + CP rats exhibited a significant increase in MAP
when compared to WKY + CP rats. Whereas, SHR +
VIPER rats had significantly reduced MAP starting from
day 4, and it remained lower for the duration of the
study (at day 14, 170 ± 1.1 versus 142 ± 1.5 mmHg,
P <0.05) when compared to SHR + CP rats. WKY + CP
and WKY + VIPER did not differ significantly.
Toll-like receptor 4 blockade in the paraventricular
nucleus attenuated cardiac hypertrophy in hypertensive
rats
To assess cardiac hypertrophy in the rats, heart weight
was recorded at the end of experimental period. The
heart weight to body weight ratio (HW/BW) was
Figure 5 Effect of bilateral intra-PVN infusion of VIPER on mean arterial blood pressure (MAP, in millimeters of mercury) and cardiac
hypertrophy in WKY and SHR rats. (A) SHR + CP group had significantly increased MAP when compared to WKY + CP rats. Interestingly,
infusion of VIPER in PVN of SHR rats for 14 days resulted in significant decrease in MAP, starting from day 4 of VIPER infusion; (B) heart weight to
body weight ratio; and (C) mRNA expression of atrial natriuretic peptide (ANP) in tissue obtained from left ventricle. Values are mean ± SE; n = 8/
group for mRNA analysis and n = 14 for MAP. *P <0.05 SHR + CP versus WKY + CP; #P < 0.05 SHR + VIPER versus SHR + CP; ***P <0.001 : ANP, Atrial
Natriuretic Peptide; CP, control peptide; MAP, mean arterial pressure; PVN, paraventricular nucleus; SHR, spontaneously hypertensive rat; TLR4,
Toll-like receptor 4; VIPER, viral inhibitory peptide of TLR4; WKY, wistar-Kyoto.
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Additionally, ANP, a molecular marker of cardiac
hypertrophy was estimated in heart tissue using real
time RT-PCR. Increased cardiac hypertrophy was ob-
served in SHR + CP rats compared with WKY + CP
rats, as indicated by a significantly increased HW/BW
ratio and ANP levels in SHR + CP group (Figure 5B
and C). VIPER treatment in SHR rats caused a signifi-
cant decrease in the HW/BW ratio as well as ANP
levels in comparison with SHR + CP, suggestive of
reduced cardiac hypertrophy by blockade of TLR4
within the PVN of SHR. These data suggest a
role for TLR4 in the PVN of the brain on MAP
regulation and cardiac hypertrophy in the essential
hypertension.
Toll-life receptor 4 blockade altered expression of pro- and
anti-inflammatory cytokines in hypertensive rats
To determine the effect of TLR4 blockade within the
PVN on inflammatoy response in hypertension, weexamined the levels of pro-inflammatory cytokines
(PICs), TNF-α and IL-1β mRNA (Figure 6A-B) and
protein (Figure 6 C-D) levels in the PVN by real time
RT PCR and western immunoblot, respectively. We
observed that SHR + CP rats exhibited marked in-
crease in TNF-α and IL-1β expression compared to
WKY + CP rats in their PVN. Interestingly, this
upregulation of TNF-α and IL-1β was significantly at-
tenuated in SHR + VIPER group. However, VIPER
infusion did not affect PICs levels in WKY rats.
Furthermore, IL-10 gene and protein expression in
the PVN tissue was measured to assess the effect of
TLR4 blockade on anti-inflammatory axis. A signifi-
cant reduction in IL-10 gene and protein expression
in the SHR + CP compared with the WKY + CP rats
was evident (Figure 6 C and E). Interestingly, SHR +
VIPER group had significantly higher levels of IL-10
in comparison with SHR + CP rats; whereas there was
no difference between WKY + CP and WKY + VIPER
groups.
Figure 6 Effects of bilateral intra-PVN infusion of VIPER on gene and protein expression of pro- and anti-inflammatory cytokines and
iNOS in WKY and SHR rats. (A) mRNA expression of TNF-α; (B) mRNA expression of IL1-β; (C) A representative immunoblot; (D) densitometric
analysis of protein expression of TNF-α, IL1-β, IL10 and iNOS; (E) mRNA expression of IL10; and (F) mRNA expression of iNOS. Values are means ±
SE. n = 8 in each group for mRNA analysis and n = 5 in each group for western blot. ***P <0.001; *P <0.05 SHR + CP versus WKY + CP; #P <0.05
SHR + VIPER versus SHR + CP: CP, control peptide; IL-1β, interleukin-1 beta; IL10, interleukin10; iNOS, inducible nitric oxide; PVN, paraventricular nu-
cleus; SHR, spontaneously hypertensive rat; TLR4, Toll-like receptor 4; TNF-α, tumor necrosis factor-alpha; VIPER, viral inhibitory peptide of TLR4;
WKY, wistar-Kyoto. Furthermore, IL-10 gene and protein expression in the PVN tissue was measured to assess the effect of TLR4 blockade on anti-
inflammatory axis. A significant reduction in IL-10 gene and protein expression in the SHR + CP compared with the WKY + CP rats was evident
(Figure 6 C and E). Interestingly, the SHR + VIPER group had significantly higher levels of IL-10 in comparison with the SHR + CP rats, whereas
there was no difference between the WKY + CP and WKY + VIPER groups.
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synthase levels in the hypertensive rats
Hypertension is found to modulate iNOS expression.
iNOS is induced primarily by PICs and is another marker
of inflammation. We found that SHR +CP rats had
marked increase in mRNA and protein levels of iNOS
(Figure 6 C and F) in comparison with WKY +CP rats.
Importantly, chronic infusion of VIPER in the PVN caused
a significant decrease in mRNA and protein expression of
iNOS in the SHR rats but not in the WKY rats.Toll-like receptor 4 blockade attenuates NFκB activity in
hypertensive rats
We performed NFκB binding activity assay using the
PVN tissues of all rat groups as illustrated in Figure 7A.
As expected, we observed that SHR + CP rats had sig-
nificantly higher NFκB activity in the PVN homogenates
than WKY + CP rats. Interestingly, this response was
abolished by chronic VIPER infusion within the PVN of
SHR rats. However, VIPER infusion did not affect NFκB
activity in the WKY rats.
Figure 7 Effects of bilateral intra-PVN infusion of VIPER on (A)
NFκB activity of PVN tissue and (B) plasma levels of norepinephrine
(NE) in WKY and SHR rats. NFκB activity assay showing increased
activity in PVN of SHR + CP rats when compared to WKY + CP rats,
whereas, VIPER infusion in SHR rats resulted in significant reduction in
the NFκB activity. Similar trends were observed with regard to plasma
norepinephrine levels as well. Values are means ± SE. n = 6/group for
NFκB activity; n = 8 for plasma NE analysis. ***P <0.001. CP, control
peptide; NE, norepinephrine; NFĸB, nuclear factor-kappa B; PVN, paraventricular
nucleus; SHR, spontaneously hypertensive rat; TLR4, Toll-like receptor 4; TNF-α,
tumor necrosis factor-alpha; VIPER, viral inhibitory peptide of TLR4;
WKY, wistar-Kyoto.
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norepinephrine levels in hypertensive rats
SHR + CP group had an increased circulating plasma NE
(Figure 7B) concentration when compared to WKY + CP
rats. Interestingly, inhibition of TLR4 using VIPER in
the PVN caused a significant reduction in the plasma
levels of NE in SHR but not in WKY.
Discussion
In the present study, we investigated the effects of bilat-
eral inhibition of TLR4 within the hypothalamic PVN of
the brain of SHR rats, which are well established as a
genetic model of human essential hypertension. The sali-
ent findings of this study are as follows:
1. SHR rats had robust increase in TLR4 levels in the
PVN, which was mostly localized in the neurons and
microglia. These results were associated with
increase in HMGB1 levels within the PVN as well as
in the circulation.
2. Blockade of TLR4 within the PVN prevented, at
least in part, the increase in blood pressure in SHR
and attenuated cardiac hypertrophy in SHR.3. TLR4 inhibition in the PVN attenuates pro-
inflammatory cytokines, iNOS, and transcription
factor, NFκB activity; whereas, TLR4 inhibition
causes an increase in anti-inflammatory IL-10 in the
PVN of hypertensive SHR rats.
4. TLR4 blockade resulted in significant reduction in
circulating plasma NE in SHR rats. In the present
study, we observed a significant increase in the
TLR4 gene and protein expression within the PVN
of hypertensive rats. More importantly, our double-
labeling immunofluorescence staining of the frozen
floating PVN sections demonstrated that TLR4
protein is present mainly in neurons and microglia
(albeit at much lower level) and not so much in the
astrocytes, indicating that TLR4 upregulation in
neurons and microglia of the PVN could be one of
the characteristics of hypertensive response observed
in these animals. To the best of our knowledge, the
present study is the first to demonstrate that
increased TLR4 expression in the PVN contributes
to a hypertensive response in a genetic model of
hypertension. Furthermore, a corresponding increase
in the HMGB1 levels in the PVN and in circulation
indicates that TLR4 acts via the HMGB1. These
results provide mechanistic evidence that detrimental
effects seen in genetic hypertension are mediated, at
least in part, by TLR4 in the PVN and that inhibition
of TLR4 attenuates hypertensive response, possibly via
downregulation of inflammatory components and
upregulation of anti-inflammatory mediators in the
PVN. Taken together, the results of this study suggest
TLR4 as a newer therapeutic target for effective
control of blood pressure. The proposed mechanism
by which TLR4 exerts its role in hypertension is
depicted in Figure 8.
Hypertension is a chronic inflammatory condition. In
this context, immune system works as a first line of
defense against an insult or tissue injury and acts via
mechanism of inflammation. This critical response is ini-
tiated by identification of pathogen-associated molecular
patterns by pathogen recognition receptors present on
cell membrane [12]. TLRs are one such pathogen recog-
nition receptors, which are considered a major compo-
nent of the innate immune system. To date, 13 TLRs
have been cloned in mammals and each TLR have a dis-
tinct function in innate immune recognition [35]. TLRs
are type I transmembrane glycoproteins. They can be
classified into two groups according to their subcellular
localization: TLR1, TLR2, TLR4-6 and TLR11 are
expressed on the plasma membrane, whereas TLR3,
TLR7 and TLR9 are found in the endosomal compart-
ment [36]. Human TLR4 was the first characterized
mammalian TLR [37]. In addition to immune cells,
Figure 8 Schematic illustrating proposed mechanism of TLR4
activation and downstream signaling in the PVN hypertension.
One of the mechanisms of sustained elevation of blood pressure in
essential hypertension could be due to increased activation of TLR4
in the PVN and subsequent activation of NFκB pathway to produce
inflammatory alterations, sympathoexcitation, and cardiac
hypertrophy. Blockade of TLR4 in the PVN attenuates hypertensive
response and prevents detrimental inflammatory changes associated
with hypertension. Besides reduction in MAP in VIPER treated SHR
rats, we also observed reduction in plasma NE levels. Therefore
these beneficial effects might be also due to reduction in plasma NE
and HMGB1 levels as observed in this study: HMGB1, high mobility
group box 1; MAP, mean arterial pressure; NE, norepinephrine; NFĸB,
nuclear factor-kappa B; PVN, paraventricular nucleus; SHR,
spontaneously hypertensive rat; TLR4, Toll-like receptor 4; VIPER,
viral inhibitory peptide of TLR4.
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mune cells of the cardiovascular system [38], brain
[39,40], neuronal culture stimulated with LPS [12], and
vascular smooth muscle cells [41], indicating that body
tissues have control over their own immune response.
Our current results together with previous reports sug-
gest role of TLR4 in hypertension. Although hyperten-
sion is a chronic inflammatory condition, the role played
by TLR4 , which responds to endogenous DAMPs, in
pathogenesis of hypertension is largely unclear. More-
over, it is well known that the PVN is central in initi-
ation and development of hypertension, the role of
TLR4 within the PVN of genetic model of human essen-
tial hypertension has never been investigated before.
In this study, to test our hypothesis that hypertensive
response observed in SHR rats could be mediated by ac-
tivation of TLR4 in the PVN, we chronically infused a
specific TLR4 blocker (VIPER) or control peptide (CP)
by intra-PVN route in the SHR rats and their normoten-
sive control, the WKY rats. We observed a significant
reduction in MAP in the hypertensive rats that received
VIPER (SHR + VIPER) when compared to thehypertensive rats receiving the control peptide (SHR +
CP), and saw no comparable changes in WKY rats re-
ceiving VIPER. Additionally, our telemetric recordings
showed a significant reduction in MAP in the SHR +
VIPER group starting from day 4 of the VIPER infusion,
which remained lower until the end of the experiment.
In keeping with our results, a previous report showed
that a neutralizing TLR4 antibody reduces blood pres-
sure in the SHR rats [3]. The present study provided fur-
ther evidence that inhibition of TLR4 in the PVN
partially restored blood pressure to normal levels, sup-
porting that TLR4, along with other central mechanisms,
plays an important role in BP regulation [42-44].
Hypertension is characterized by increased cardiac
hypertrophy and cardiac dysfunction. [45]. Therefore, we
investigated whether TLR4 blockade in the PVN is car-
dioprotective in hypertensive rats. SHR + CP rats had in-
creased ANP levels and HW:BW when compared with
WKY + CP rats, indicating presence of cardiac hyper-
trophy in SHR as also reported in previous studies
[30,46]. More importantly, TLR4 blockade within the
PVN resulted in a significant reduction in ANP and the
HW:BW ratio in hypertensive rats, suggesting reduced
cardiac hypertrophy by TLR4 blockade. A handful of
previous studies have reported that TLR4 deficiency pro-
tects the myocardium in Angiotensin II-induced hyper-
tension in rat [40] and from ischemia/reperfusion injury
in mice [47]. Taken together, the current findings sug-
gest the role of brain TLR4 in cardiac hypertrophy in
hypertension.
Each TLR recognizes specific pathogen-associated mo-
lecular patterns (PAMPs) in microbial injury. TLRs, es-
pecially TLR4, can also be stimulated by host-derived
molecules, known as damage-associated molecular pat-
tern molecules (DAMPs) [16,17]. Of several DAMPs,
high mobility group box-1 (HMGB1) is the most import-
ant DAMP that has been implicated in various inflam-
matory conditions. In response to injury or infection,
HMGB1 is released actively by immune cells and pas-
sively by insulted cells into the extracellular space and
initiates an inflammatory response [15-17]. Therefore,
one possible mechanism by which TLR4 is activated in
hypertension could be via upregulation of HMGB1. Re-
inforcing this hypothesis, in the present study, hyperten-
sive rats were found to have significantly increased levels
of HMGB1 in the PVN as well as in circulation. Similar
secretion of HMGB1 and expression of TLR4 was ob-
served in ischemic brain injury [48]. However, the novel
finding of the present study is that inhibition of TLR4
within the PVN resulted in a significant decrease in
HMGB1 levels in the PVN and circulation. Given that
the TLR4 blockade reduces MAP, it can be postulated
that TLR4 plays role in hypertension, possibly via
HMGB1. Whether other known ligands of TLR4, such
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hypertensive animals is not clear at this time and needs
to be investigated in detail. Nevertheless, the present
findings provide strong evidence that TLR4 within the
PVN plays a critical role in the pathogenesis of hyper-
tension, at least in part, due to increased binding with
its specific DAMP, HMGB1.
Once a TLR recognizes an endogenous DAMP, activa-
tion of inflammatory signaling begins [16,17]. Moreover,
an inflammatory response in hypertension is character-
ized by a peripheral and central increase in various PICs,
in particular, TNF-α and IL-1β [20,49,50]. In addition,
PICs are known to induce iNOS expression in hyperten-
sion [22]. Therefore, to investigate whether TLR4 signal-
ing within the PVN contributes to inflammatory
response seen in hypertension, we measured the gene
and protein expression of TNF-α, IL-1β and iNOS in the
PVN tissue. We found that chronic TLR4 inhibition in
hypertensive rats causes a significant reduction in TNF-
α and IL-1β levels, as well as iNOS levels, in the PVN.
Additionally, anti-inflammatory cytokine IL-10 was
found to be significantly increased in VIPER-infused
hypertensive rats. These results clearly suggest the role
of TLR4, specifically within the PVN in inflammatory re-
sponse in hypertension. Although not within the PVN, a
handful of previous reports showed that systemic injec-
tion of anti-TLR4 antibody decreases serum levels of IL-
6 in SHR [3] and systemically infused TLR4 antagonist
reduces serum levels of inflammatory markers in heart
failure animals [51]. Similarly, another study has shown
that the TLR4 and PICs were increased in the heart tis-
sues of the SHR rats [45]. It is noteworthy that although
these studies show suppression of inflammation in the
end-organs, none of the studies were able to point out
the role of the brain in hypertension Given our current
findings that TLR4 is dramatically upregulated within
the PVN and that the TLR4 blockade attenuates MAP,
our results suggest a vital role played by hypothalamic
TLR4 in hypertensive response. Hence, an improvement
in MAP and cardiac function by central inhibition of
TLR4, as observed in the present study, could be attrib-
utable to a reduction in iNOS and PICs. Supporting our
results, a recent study has demonstrated that ablation of
iNOS delays cardiac hypertrophy and contractile dys-
function in mice with aortic banding-induced hyperten-
sion [52]. Binding of free HMGB1 to TLRs leads to the
production and release of PICs [53]. Our findings that
HMGB1 levels were increased both in the circulation
and in the PVN together with increase in PICs ,iNOS
and plasma NE suggest that TLR4 participates in the in-
flammatory process associated with hypertension leading
to sustained activation of NFκB pathway to produce in-
flammatory alterations, sympathoexcitation, and cardiac
hypertrophy in SHR rats.NFκB is one of the most important downstream tran-
scription factors responsible for the transcription of PICs
and iNOS. It is also well established that TLR4 shares
the same NFκB signaling pathways. Given that VIPER
injection into the PVN of hypertensive rats reduces PICs
and iNOS levels, one possible mechanism by which
TLR4 inhibition in PVN exerts its beneficial effects
could be via downregulation of NFκB. Reinforcing this
hypothesis, the present study showed that the TLR4
blockade causes downregulation of NFκB activity in
SHR rats. To the best of our knowledge, the present
study is the first to investigate the downstream signaling
mechanism of TLR4 within the PVN in regulation of
MAP. Nevertheless, these results clearly suggest that at-
tenuation of NFκB activity might be attributable to re-
duced inflammation, which in turn leads to disruption of
a detrimental positive feedback cycle involved in cardiac
remodeling and the progression of hypertension.
It has been well established that sympathetic hyper-
activity contributes to cardiac remodeling in hyperten-
sion via an increase in TNF-α production [54] and NFκB
activation leading to end organ damage [55]. In accord-
ance with these previous reports, in the present study,
the SHR rats showed higher circulating plasma levels of
NE (an indirect indicator of sympathetic activity), indi-
cating increased sympathetic outflow compared to WKY
rats. However, a novel finding of this study is that inhib-
ition of TLR4 in the PVN with VIPER resulted in a
dramatic reduction in plasma levels of NE in the hyper-
tensive rats, suggesting that upregulation of brain TLR4
plays a key role in sympathoexcitation as observed in
hypertensive animals. The mechanism by which TLR4
increases sympathetic output in SHR is not clear at this
time. However, given that inhibition of TNF-α or NFκB
in the PVN decreases arterial pressure [30] and sympa-
thetic activity [56], it is plausible to suggest that activa-
tion of TLR4 signaling induces sympathetic hyperactivity
possibly via increased PICs. As evidence, Ogawa et al.
demonstrated that siRNA-mediated inhibition of brain
TLR4 decreases urinary norepinephrine excretion in rats
with myocardial infarction [44]. Nonetheless, the results
of the present study suggest that activation of TLR4 in
the PVN of the brain leads to increased sympathetic
activation in an animal model of essential hypertension.
Limitations
There are two common pathways shared by TLRs,
namely the myeloid differentiation factor 88 (MyD88)-
dependent and the MyD88-independent pathways
[57,58]. An increase in PICs expression induced through
NFκB activation is the main feature of the MyD88-
dependent pathway, whereas activation of interferon-γ
regulatory factor 3 is characteristic of the MyD88-
independent pathway [59,60]. Given our findings that
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lieve that the MyD88-dependent pathway is involved in
this process. Specific adaptors and possible ligands,
other than HMGB1 involved in TLR4 signaling, need to
be investigated and could be a focus for future studies.
Furthermore, here we explored the PVN region, al-
though there are multiple cardiorelevant sites in the
brain that can play a role in modulating the hypertensive
response. However, we feel that the PVN is of import-
ance because of its recognized integrative functions.
Nonetheless, the current data undermines the key role
played by brain TLR4 signaling in the pathogenesis of
hypertension and suggest that TLR4 as a novel thera-
peutic target for the treatment of essential hypertension.Conclusions
To summarize, TLR4 regulates various diseases in an
NFκB-dependent manner. It has been shown to increase
cardiac hypertrophy and dysfunction in animal models
of heart failure and hypertension. Here, we show that
the SHR rats exhibit dramatic upregulation of TLR4
within the cellular components of the hypothalamic
PVN. More importantly, inhibition of TLR4 by bilateral
microinjection into the PVN of the SHR rats delays the
progression of hypertension; reduces cardiac hyper-
trophy; attenuates PICs, iNOS, and NFκB, as well as NE
levels; and improves anti-inflammatory IL-10 levels
within the PVN. Additionally, our results identify TLR4
as a specific TLR, and HMGB1 as one of its endogenous
ligands that plays a vital role in the hypertensive re-
sponse. Taken together, the present study shows activa-
tion of HMGB1 as an upstream phenomenon and
activation of inflammatory signals as a downstream
pathway in TLR4 signaling within the PVN of hyperten-
sive rats. Overall, our data for the first time demonstrate
that an excessive increase in TLR4 within the PVN plays
an important role in initiation of the inflammatory
process observed in essential hypertension.
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